C. Cannata MSc (Cristiana)
Promovendus - Environmental Science
6525 AJ NIJMEGEN
Interne postcode: 89
6500 GL NIJMEGEN
I am a PhD candidate with expertise on environmental risk assessment (ERA) of pharmaceuticals.
I am working for the PREMIER project, being part of a consortium composed of 25 partners from the public and private sector, which contributes to a sustainable future by proactively managing the environmental impact of medicines.
In the frame of the PREMIER project, I am in charge of (I) prioritising active pharmaceuticals ingredients (APIs) that are suspected to cause a high risk for the environment, (II) contributing to the development of a publicly accessible database with ERA data on human pharmaceuticals (e.g. ecotoxicity data, fate parameters, chemical identifiers), (III) collaborating with the editorial team, (IV) drafting guidance documents with relevant stakeholders.
- The Prioritisation and Risk Evaluation of Medicines In the EnviRonment (PREMIER) project brings together a world-leading multi-disciplinary consortium composed of 25 partners from the public and private sectors working to contribute to a sustainable future by proactively managing the environmental impact of medicines. The PREMIER aims to design a novel information and assessment system for identifying and addressing environmental risks of medicines, steering the development of medicines in a greener direction and supporting the establishment of a new European standard for environmental protection. This project is funded by the Innovative Medicines Initiative (IMI) - Europe’s partnership for health, representing the world's biggest public-private partnership in the life sciences. The IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA). Meer informatie